Poster presentation schedule

Tuesday, 21 November 2023
09:30 – 10:25

Clinical Pharmacology	
P500	**Computational video analysis for treatment and deprescribing evaluation in ageing mice** Dr Kenji Fujita, Kolling Institute, The University of Sydney
P502	**Outcomes of considering goals of care in medication review: a systematic review** Dr Nashwa Masnoon, Kolling Institute, The University of Sydney and Northern Sydney Local Health District
P504	**Developing a tool to evaluate organisational culture and psychotropics use in RACF** Boyi Chen, The University of Sydney
P506	**Identifying priorities for medication management resources for people with dementia and carers** Dr Mouna Sawan, The University of Sydney
P508	**Cannabidiol in sport and exercise** Prof Michael Kennedy, Clinical Pharmacology, St Vincent's Hospital Sydney
P510	**An efficient HILIC-MS/MS method for monitoring metformin in human plasma** A/Prof Mei Zhang, Department of Medicine, The University of Otago - Christchurch
P512	**Ethnic differences in the safety and efficacy of tyrosine kinase inhibitors** Nicki Kyriacou, The University of Sydney
P514	**Thioguanine efficacy, safety and TDM in IBD patients in New Zealand** Prof Murray Barclay, Christchurch Hospital
P516	**The effect of compulsory indications in electronic hospital prescriptions on prescriber behaviour** Lorna Pairman, The University of Otago

Drug Discovery	
P518	**Influence of tumour microenvironment on the activity of breast cancer therapeutic agents** Xiaodan Zhang, The University of Melbourne
P520	**Calcium signalling and the breast cancer microenvironment** Dr Farzaneh Forouz, The University of Queensland
P522	**Inducing conformational bias via fluorination to enhance selectivity and potency of imipramine** Ishika Jaitly, UNSW Sydney
P524	**TRPA1 expression in joints and DRGs of monoiodoacetate-induced rat knee OA pain** Scarlett Desclaux, Mahidol University
P526	**Exploring calcium signalling remodelling during adaptive cancer drug tolerance** Melanie Robitaille, The University of Queensland
P528	**8-Shogaol suppresses rheumatoid arthritis by direct inhibition of TAK1** Yong Joon Lee, Yonsei University
P530	**Combining LC-MS/MS with bioinformatic approaches for understanding bioactivities of propolis** Eun Heo, Yonsei University
P532	**Hydroxychavicol inhibits expression and activity of MMP-9 induced by RANKL in osteoclasts** Wisuttaporn Inthanop, Faculty of Medicine Ramathibodi Hospital, Mahidol University
P534	**Oleanolic acid and syringic acid induce fat browning through UCP1 activation** A/Prof Chang Ik Choi, Dongguk University
P536	**Exploring molecular determinants underpinning high potency of MIPS3215 at adenosine A2B receptor** Cam Sinh Lu, Monash University
P538	**Exploring A2B receptor regulated human cardiac fibroblast phosphoproteome for fibrosis target discovery** Joel Coffie, Monash University
P540	**A novel single-cell fluorescence-microscopy based analysis for detection of biomarkers of cellular-senescence** Vijayraghavan Seshadri, The University of Tasmania
P565	**Exploring Spexin-1 and Predicted Spliceoforms: Insights into GPR161 and GAL2R Signalling** Kinjal Patel, UNSW Sydney

Tuesday, 21 November 2023
09:30 – 10:25

Respiratory and Inflammation	
P542	**Re-examining IRAK3 - an essential homeostatic checkpoint immune protein** Dr Helen Irving, La Trobe University
P544	**Ebselen is unable to restore established cigarette smoke-induced neurocognitive dysfunction** Alina Akhtar, RMIT University
P546	**Human osteoclast differentiation after induction by mRNA of NFATc1** Dr Sirada Srihirun, Mahidol University
P548	**Pulmonary and vascular consequences of influenza A virus infection in atherosclerotic mice** Madison Coward-Smith, RMIT University

Innovation and Industry	
P550	**Development of a Precision Medicine Competency Framework for the Therapeutics Industry** Dr Orin Chisholm, The University of Sydney
P552	**New methods for designing patient-centred clinical trials for epilepsy and cannabidiol drugs** Linda Truong, The University of Newcastle
P554	**Nonclinical and Manufacturing Considerations for Novel Live Biotherapeutic Products** Dr Sharleen Menezes, Novotech
P556	**Nonclinical and CMC Considerations for the Development of siRNA Therapeutics** Sweta Kumar, Novotech

Toxicology	
P558	**Stress-driven suppression of the Hippo pathway accelerates liver injury** Ja Hyun Koo, Seoul National University
P560	**Computational models of retinoic acid receptor antagonists acting as endocrine disrupting chemicals** Raymond Lui, The University of Sydney
P561	**MEHP-induced apoptosis, autophagy, and endoplasmic reticulum stress in human neurons and astrocytes** Ratchanon Sukprasert, Faculty of Allied Health Sciences, Burapha University
P563	**Fluoroquinolone ameliorates cadmium-induced pro-inflammatory cytokine production in human astrocytes** Suttinee Phuagkhaopong, Department of Pharmacology, Faculty of Medicine, Chulalongkorn University

Clinical Pharmacology

P501	**Sustainability of in-hospital deprescribing: a scoping review with a systematic approach**
	Angela John, The University of Sydney
P503	**Co-designing medication management resources for people with dementia and carers during hospitalisation**
	Alexander Clough, The University of Sydney
P505	**Patient's experience of a psychiatric, alcohol and non-prescription drug assessment (PANDA) unit**
	Hannah Paul, UNSW Sydney
P507	**Effects of alcohol on blood glucose in patients with type-1 diabetes mellitus**
	A/Prof Hesham Al-Sallami, School of Pharmacy, The University of Otago
P509	**Routine Therapeutic Drug Monitoring of Rivaroxaban: Experience at a Tertiary Center**
	Dr Paul Chin, The University of Otago
P511	**Equity and Quality Use of Medicines in people presenting to PANDA Unit**
	Dr Jana Stojanova, St Vincent's Hospital Sydney
P513	**Four-year review of NZ laboratory infliximab/adalimumab concentrations indicates potential for improved dosing**
	Prof Murray Barclay, Christchurch Hospital
P515	**The Utility of Education Materials and Decision Aids to Guide Medication Management**
	Joseph Boutros, The University of Sydney

Drug Discovery

P517	**CK1δ inhibitor PF670462 has anti-tumorigenic activity in the TNBC cell line, MDA-MB-231**
	Jana Zielinski, The University of Melbourne
P519	**Modulation of T- type Calcium Channel 3.1 by Cannabidiol and enantiomer +CBD**
	Dr Chris Bladen, Macquarie University
P521	**Targeting casein kinase 1 delta/epsilon in hepatocellular carcinoma**
	Gretel Happell, The University of Melbourne
P523	**Developing nanobodies as subtype-selective α1A adrenergic receptor tools**
	Saund Yadanar, Monash University
P525	**Developing a human cell model to study calcium signalling during coronavirus infection**
	Shao Ming Chan, The University of Queensland
P527	**Assessing gene expression of pannexin isoforms in breast cancer cell lines**
	Monami Ghosal, The University of Queensland
P529	**Gene expression of calcium signalling modulators in SARS-CoV-2 infection**
	Mia Akison, The University of Queensland
P531	**Selective killing of mTORC1-hyperactive cancer cells through targeting the RUVBL1/2-TTT pathway**
	Ji Su Lee, Yonsei University
P533	**Hydroxychavicol inhibits RANKL-induced expression of osteoclast-specific genes**
	Pitchanun Kongphanich, Mahidol University
P535	**The effect of C.racemosa extract on anti-wrinkle and anti-melanogenesis in skin cells**
	Ratchanon Sukprasert, Faculty of Allied Health Sciences, Burapha University
P537	**Developing an optogenetic system to shine a light on intracellular GPCR signalling**
	Chantel Mastos, Monash University
P539	**Characterisation of the pro-atherosclerotic orphan G protein-coupled receptor, GPR146**
	Brendan Wilkins, UNSW Sydney

Respiratory and Inflammation

P541	**A soft microenvironment uncouples TGF-beta signaling from fibrogenesis in human pulmonary fibroblasts**
	Avanka Gunatilaka, The University of Melbourne
P543	**Bombesin Receptor Subtype 3 as a potential target for lung adenocarcinoma**
	Mariah Stavrou, UNSW Sydney
P545	**Casein kinase 1 delta/epsilon inhibition: a promising solution to unaddressed airway remodelling**
	Nguyen Thi Hanh Tran, The University of Melbourne
P547	**Involuntary exercise did not improve cigarette smoke-induced anxiety-like behaviour in male mice.**
	Rana Alateeq, RMIT University
P549	**A 3D mesothelioma co-culture model to improve translational potential of immunotherapy treatments**
	Aimee Stenekes, University of Technology Sydney

Innovation and Industry	
P551	**Bone regeneration potential of 3D printed hydroxyapatite in a rat model** Ticomporn Luangwattanawilai, Mahidol University
P553	**What is a Non-Significant Risk Device Clinical Study?** Melissa Dworak, Novotech
P555	**Automated In-Vitro Population Bioequivalence for Inhaled Products Using Phoenix® WinNonlin®** Dr Chandramouli Radhakrishnan, Certara

Toxicology	
P557	**Oxyresveratrol and resveratrol attenuate cadmium-induced cytokine release in human astrocytes** A/Prof Pornpun Vivithanaporn, Mahidol University, Faculty Of Medicine Ramathibodi Hospital - Bangkok
P559	**Impact of target expression on target safety assessment of ADCs** Phumzile Sikakana, ApconiX
P562	**Application of Bayse Theorem to augment machine learning predictions of Ames mutagenicity** Daniella James-New, The University of Sydney
P564	**Acute toxicity of Thai PM 2.5 in zebrafish embryos** Pinnakarn Techapichetvanich, Mahidol University

Poster presentation schedule

Wednesday, 22 November 2023
09:30 – 10:25

Cardiovascular

P600	**The Role of Interleukin-18 Receptor Accessory Protein in Hypertensive Chronic Kidney Disease** Buddhila Wickramasinghe, La Trobe University
P602	**Comparing the anti-fibrotic potential of exosome-based therapies in human myofibroblasts in vitro** Jennie Charoenphannathon, Monash University
P604	**RAGE expression and function in myometrial arteries during gestational diabetes.** Dr Timothy Murphy, UNSW Sydney
P606	**Neurogenic inflammation exacerbates urinary tract infection in mice** Harman Sharma, Flinders University
P608	**Impact of exercise on the heart in a mouse model of obesity** Nimna Perera, Monash Institute of Pharmaceutical Sciences
P610	**Sex matters– impact of HFD and low-dose SGLT2i on rodent cardiometabolic phenotype** Abhipree Sharma, Monash University
P612	**Targeting the AT4 receptor/IRAP reverses type 2 diabetes-induced cardiovascular dysfunction and remodelling** Cameron Hollands, Monash University

Drug Disposition and Response

P614	**Critical evaluation of topical zinc pyrithione anti-fungal therapeutics** Sean Mangion, The University of South Australia
P616	**Describing plasmapheresis (PLEX): PLEX, the patient and impact on therapy** Susie Welch, St Vincent's Hospital Sydney

Education

P620	**Nutrition counselling in Pharmacy Practice in Australia** Samar Elsayed, School of Pharmacy, The University of Sydney
P622	**Altered preference from online to face-to-face workshops does not influence academic outcomes** Dr Elvan Djouma, La Trobe University
P624	**Scaffolding resilience skill development across an undergraduate Pharmacy curriculum** Dr Betty Exintaris, Monash University
P626	**Accessing lecture recordings as a supplement or a substitute to lecture attendance** Dr Sheila Doggrell, Griffith University

Neuropharmacology

P628	**Novel treatments targeting neurodegeneration and inflammation attenuate repetitive mild traumatic brain injury** Dr Andrew Fenning, CQ University
P630	**Modulation of neuronal ion channels by metabolites of cannabidiol** Prof Mark Connor, Macquarie University
P632	**Epilepsy-causing proline paralog variant in GABAA-receptor display distinct functional properties between subunits** Sze Hon Kan, Brain and Mind Centre, The University of Sydney
P634	**A novel system for determining CB1 activity by employing the operational model** Humayra Zaman, Macquarie University
P636	**Modulation by CBD metabolite decreases THC signalling via CB1 in vitro** Zoe Adam, Macquarie University

Wednesday, 22 November 2023
09:30 – 10:25

Pharmacogenomics	
P638	**Personalising selection of antifungals: can we predict lack of response to voriconazole?** Eman Wehbe, The University of Sydney

Pharmacoepidemiology	
P641	**Poisonings in older adults with dementia: a systematic scoping review and meta-analysis** Ilsa Wojt, The University of Sydney
P643	**Prevalence of and risk factors for drug-related readmissions in older adults** Narisha Prasad, The University of Sydney

Urogenital and Gastrointestinal	
P645	**Consistencies between carbachol-induced contractions to clinical antimuscarinics in differently aged porcine bladders** Vineesha Veer, Bond University
P647	**Contractile response of the urothelium/lamina propria depressed by acute hypoxia in vitro** Elouise Tye, Bond University
P649	**The Functional Role of Phosphodiesterase Isoenzymes in the Isolated Porcine Urethra** Eriq Burovski, Bond University

Sponsored by:

PROTO AXIOM

Cardiovascular	
P601	**Is there now evidence for rethinking statin dose?**
	Prof Simon Dimmitt, Universities of Western Australia And Newcastle
P603	**Interleukin-1 beta via Smad2 transcription factor promotes glycosaminoglycan chain synthesising gene expression**
	Hirushi Kumarapperuma, The University of Queensland
P605	**Natriuretic peptide receptors in vascular smooth muscle cells in tissue versus culture**
	Christine Rager, Monash University
P607	**Inhibition of the AT4R/IRAP to reduce renal fibrosis in chronic kidney disease**
	Sharenya Chelvaretnam, Monash University
P611	**Lipoxin A4 improves cardiac remodelling and function in diabetes-associated cardiac dysfunction**
	Ting Fu, Monash University

Drug Disposition and Response	
P613	**Protein and RNA characterisation of rapidly maturing CLEFF4 and parent Caco2 cells**
	Dr Andrew Crowe, Curtin University
P615	**Visualising the topical delivery of retinoids**
	Sean Mangion, The University of South Australia
P617	**Antibiotic combinations against Pseudomonas aeruginosa strains with different resistance mechanisms**
	Alice Terrill, Monash University

Education	
P619	**Perceptions of third-year undergraduate pharmacology students on teamwork**
	Arani Dasanayake, Monash University
P621	**Using clinical case studies to build professional skills: A case study**
	Dr Suong N T Ngo, The University of Adelaide
P623	**Use of a baseline teamwork assessment tool in undergraduate pharmacology**
	A/Prof Lynette Fernandes, The University of Western Australia
P625	**Streamlining Nursing Home Discharges from the Acute Hospital Setting**
	Dr Betty Exintaris, Monash University
P627	**Evaluating pharmacogenomics education on medical, pharmacy and nursing student knowledge and confidence**
	Ruby Soueid, The University of Sydney

Neuropharmacology	
P629	**Osteoarthritis, opioids, & polypharmacy: deprescribing outcomes in middle-aged male & female mice**
	Charlie Gregson, Kolling Institute
P631	**Structural Insights into Positive Allosteric Modulation at the M4 mAChR**
	Michaela Kaoullas, Monash Institute of Pharmaceutical Sciences
P633	**A new system to determine Cannabinoid receptor-2 (CB2) ligand efficacy**
	Tahira Foyzun, Macquarie University
P635	**Endocannabinoid related derivatives of polyunsaturated fatty acids (PUFAs) activate TRPV1 ion channel**
	Atnaf Abate, Macquarie University

Wednesday, 22 November 2023

12:30 – 13:25

Pharmacoepidemiology

P637	**Real-world evidence of antipsychotic utilization in Australia (2000–2021) using two datasets** Ramya Padmavathy Radha Krishnan, The University of Sydney
P639	**Psychotropic use in older people with and without dementia in Australia** Edward Lau, The University of Sydney
P642	**The availability of mobile applications to facilitate deprescribing: A scoping review** Lina Okati, The University of Sydney
P644	**Six-country comparison of antimicrobial consumption in Latin American hospitals** Maria Jose Alfonso Arvez, Monash University

Urogenital and Gastrointestinal

P646	**5-HT3 receptors moonlight in mitochondria above their steady job at plasma membrane** Santosh RamaBhadra Rao Tata, La Trobe University
P648	**Lactobacillus salivarius HHunMin-U enhances the innate immune response against Norovirus infection** Jay-young Jo, Yonsei University
P650	**Comparison of diabetes-induced bladder dysfunction in vitro and in vivo** Aidan Mckeon, Bond University